Preservation with $\alpha_1$-antitrypsin improves primary graft function of murine lung transplants

Jessica Götzfried, MSc,a,1 Natalia F. Smirnova, PhD,a,1 Carmela Morrone, MSc,a Brice Korkmaz, PhD,b Ali Önder Yildirim, PhD,a,c Oliver Eickelberg, MD,a,d and Dieter E. Jenne, MDa,c,e

From the Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München and University Hospital of the Ludwig-Maximilians University, Munich, Germany; INSERM U-1100, "Centre d’Etude des Pathologies Respiratoires" and Université François Rabelais, Tours, France; German Center for Lung Research, Munich, Germany; Pulmonary Sciences and Critical Care Medicine, University of Colorado, Denver, Colorado, USA; and the Max Planck Institute of Neurobiology, Planegg-Martinsried, Germany.

Keywords:
Primary graft dysfunction; ischemia-reperfusion injury; alpha-1-antitrypsin; elastase; proteinase 3; animal models; lung transplantation

Background: Vascular damage and primary graft dysfunction increase with prolonged preservation times of transplanted donor lungs. Hence, storage and conservation of donated lungs in protein-free, dextran-containing electrolyte solutions, like Perfadex, is limited to about 6 hours. We hypothesized that transplanted lungs are protected against neutrophil-mediated proteolytic damage by adding $\alpha_1$-antitrypsin (AAT), a highly abundant human plasma proteinase inhibitor, to Perfadex.

Methods: A realistic clinically oriented murine model of lung transplantation was used to simulate the ischemia–reperfusion process. Lung grafts were stored at 4°C in Perfadex solution supplemented with AAT or an AAT mutant devoid of elastase-inhibiting activity for 18 hours. We examined wild-type and proteinase 3/neutrophil elastase (PR3/NE) double-deficient mice as graft recipients. Gas exchange function and infiltrating neutrophils of the transplanted lung, as well as protein content and neutrophil numbers in the bronchoalveolar lavage fluid, were determined.

Results: AAT as a supplement to Perfadex reduced the extent of primary graft dysfunction and early neutrophil responses after extended storage for 18 hours at 4°C and 4-hour reperfusion in the recipients. Double-knockout recipients that lack elastase-like activities in neutrophils were also protected from early reperfusion injury, but not lung grafts that were perfused with a reactive center mutant of AAT devoid of elastase-inhibiting activity.

Conclusions: PR3 and NE, the principal targets of AAT, are major triggers of post-ischemic reperfusion damage. Their effective inhibition in the graft and recipient is a promising strategy for organ usage after storage for >6 hours.

J Heart Lung Transplant 2018;37:1021–1028
© 2018 The Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ischemia increases the extent of metabolic and structural changes in the transplant in the absence of cellular and blood plasma and, subsequently, the intensity of the early innate immune response in the transplanted organ after the onset of reperfusion.

Irreversible damage to transplanted lung tissue after cold ischemic storage is primarily caused by the reintroduction of blood plasma and cellular blood components at body temperature after transplantation, particularly by infiltrating neutrophils, and increases with the duration of oxygen deprivation. As activated neutrophils release large amounts of elastase-related serine proteases, some perioperative treatment options for the recipient have been explored experimentally in animal models using protease inhibitors such as bovine aprotinin, Lex032, and α1-antitrypsin (AAT). In those studies, intravenous or intraperitoneal administration of inhibitors has been used to further raise the already high plasma concentrations of protease inhibitors in the circulation. We suggested that some inhibitors applied in these studies did not display the appropriate inhibitory profile, or flooded the inhibitor-depleted graft after ex vivo perfusion and in vivo reperfusion too late to efficiently protect the transplanted organ against infiltrating activated neutrophils.

The beneficial effects of protease inhibitors, particularly AAT, have been noted in certain models of ischemia–reperfusion injury at warm body temperatures. However, the experimental conditions chosen in these examples could not appropriately mimic the challenges of ex vivo organ storage in a cold cell- and protein-free electrolyte solution such as Perfadex. Positive results from the earlier studies cannot be extrapolated to reperfusion injury after cold preservation of organs.

To develop a new clinically appropriate lung preservation protocol and to initiate a proof-of-concept study for lung transplant patients, we used an orthotopic lung transplantation model in mice and stored the transplant in AAT containing Perfadex for an extended period of 18 hours in the cold. The goal of this pre-clinical study was to test whether vascular leakage and immediate neutrophil-mediated inflammation after reperfusion could be prevented or mitigated by adding AAT to the perfusion solution during cold ischemia and whether the anticipated improvement of graft function is mediated by the direct anti-protease activity of AAT or by other anti-inflammatory, tissue-protective, and immunomodulatory properties of AAT. Our results demonstrate that AAT acts on neutrophil-derived elastase and proteinase 3 and primarily prevents immediate reperfusion damage to transplanted lung tissue by protease inhibition.

Methods

Mice

Pathogen-free C57BL/6J mice were obtained from Charles River Labs (Wilmington, MA). E122+/Prtn3−/− mice were established by Pfister et al. They were backcrossed for more than 10 generations with C57BL/6J mice. All animals were housed in rooms maintained at constant temperature and humidity with a 12-hour light cycle, and were allowed food and water ad libitum.

Study approval

All animal experiments were conducted under strict governmental and international guidelines and were approved by the local government for the administrative region of Upper Bavaria (Project 55.2-1-54-2532-120-2015).

Orthotopic lung transplant model

Orthotopic lung transplantations were performed as described elsewhere, with minor modifications. C57BL/6J male mice were used as donors, and C57BL/6J and E122+/Prtn3−/− male mice were used as recipients (all 8 to 12 weeks old). Briefly, donors were anesthetized with an intraperitoneal (IP) injection of ketamine/xylazine. The pulmonary artery (PA), bronchus, and pulmonary vein (PV) were carefully separated from one another with clamped forceps, before cuffing with 24G, 20G, and 22G cuffs, respectively. The left lung graft was perfused intravenously (IV) with 3 ml of Perfadex (5% dextran 40 [molecular weight 40,000), Na+ 138 mmol, K+ 6 mmol, Mg2+ 0.8 mmol, Cl− 142 mmol, SO4 0.8 mmol, H2PO4− plus HPO4 0.8 mmol, glucose 5 mmol). It was then perfused with Perfadex supplemented with albumin, purified recombinant wild-type AAT (AATwt), or AAT-reactive center loop mutant (AATmt) (both 1 mg/ml). To keep the solution inside the vasculature, the PA and PV were clamped with Biemer microvessel clips (B. Braun, Melsungen, Germany) and stored for 18 hours at 4°C before implantation. The recipient mouse was anesthetized with a mixture of medetomidine (1 mg/kg), midazolam (0.05 mg/kg), and fentanyl (0.02 mg/kg), then intubated and connected to a small-animal ventilator (Harvard apparatus) at a respiratory rate of 120 beats/min and a tidal volume of 300 µl. The chest was opened on the left side between ribs 3 and 4 and the native left lung retracted with a clamp. The hilar structures were carefully separated from one another with blunted forceps. The donor lung graft, prepared 18 hours earlier, was perfused IV with Perfadex to rinse away the storage solution. After arrest of the blood and air flow toward the left lung, the cuffed graft PA, bronchus, and PV were inserted into the recipient counterparts, and the connection between donor and recipient structures was secured with 9-0 sutures. The native left lung was removed and the incision in the chest was closed with a 6-0 suture, after removing all potential air bubbles from the chest. Antagonist was administered and the animal was extubated when it showed signs of spontaneous breathing. After the operation, the recipient mice were allowed to recover at 30°C and received buprenorphine (0.1 mg/kg).

Lung analyses in recipients

The mice were euthanized 4 hours after lung transplantation for assessment of primary graft dysfunction. The recipient mouse was anesthetized with a mixture of medetomidine (1 mg/kg), midazolam (0.05 mg/kg), and fentanyl (0.02 mg/kg) 4 hours after lung transplantation. After intubation (300 µl room air/120 strokes/min), a mid-line abdominal incision was performed, the diaphragm incised, and the chest opened to expose the lung and heart block. The right bronchus and PV were clamped for 5 minutes (75 µl room air, 120 strokes/min) and the oxygenation function of the transplanted left lobe was assessed by collecting blood from the left ventricle of the heart and directly measuring the partial pressure of oxygen percentage (%PO2) in a blood gas analyzer (ABL80 FLEX...
CO-OX Analyzer; Radiometer, Copenhagen, Denmark). Further, with the right bronchus still clamped, bronchoalveolar lavage (BAL) of the transplanted left lung was performed by instilling 3 × 200 µl cold phosphate-buffered saline (PBS) into the trachea. The BAL fluid was obtained by centrifugation (400g, 20 minutes, 4°C) and the protein concentration was measured with a bicinchoninic acid protein assay kit (Pierce, Catalog No. 23225; Thermo Fisher Scientific, Waltham, MA). Then, 30,000 cells from the BAL cell pellet were used for cytospin (200g, 6 minutes, 4°C) and stained with May–Grünwald (1424; Merck, Darmstadt, Germany) and Giemsa (9204; Merck) staining solution to perform a differential cell count. The lower part of the lung was kept for protein analysis (snap freezing, storage at −80°C) and the left over part was used for histology (inflation with and storage in 4% paraformaldehyde).

**Recombinant protein expression and purification**

The cDNA modification of human AATm (A355D/I356P/P357D/M358S) was introduced by amplifying the cDNA of human AAT with the forward primer DJ3608 (5′-TCGAGGACCCTGACTCATCG-3′) and the reverse primer DJ3609 (5′-ATCGATGAGTCAGGGTCC-3′). The polymerase chain reaction (PCR) product was digested with Acc I and Abs I restriction enzymes (NEB) and cloned into the respective sites of the previously modified wild-type AAT pTT5 plasmid. Recombinant clones were identified by sequencing (Eurofins). The cDNA constructs of AATwt (human M1 [V213]) and AATmt were transiently expressed in human embryonic kidney 293 (HEK293) cells, as described elsewhere.17 Harvesting of supernatants and purification of recombinant AAT variants were performed as described elsewhere.17

**Western blot analysis**

Refer to the Supplementary Material (available online at www.jhltonline.org/) for a description of Western blot analysis.

**Assay for inhibitory activity measurement**

The enzymatic activity of serine proteases NE and PR3 was determined using thiobenzylester substrates and Ellman’s reagent (5,5′-dithiobis-2-nitrobenzoic acid), or DTNB). Free thiobenzylester groups react with 2-nitro-5-thiobenzoaite ions. The rate of hydrolysis was measured at 405 nm. Inhibitory activities of 0.5 µmol/liter AATm and AATm were tested in an activity assay using 0.1 µmol/liter recombinant mouse and human NE and PR3. The remaining activity of the proteases was determined using thiobenzylester substrate (Boc-Ala-Pro-Nva-SBzl; 4008235.0010; Bachem) at 1 mmol/liter substrate concentration and 0.5 mmol/liter DTNB in activity assay buffer (50 mmol/liter Tris, 150 mmol/liter NaCl, 0.01% Triton X-100 [pH 8.0]).

**Tissue preparation**

Refer to the Supplementary Material (online) for a description of tissue preparation.

**Hematoxylin and eosin staining**

Refer to the Supplementary Material (online) for a description of hematoxylin and eosin (H&E) staining.

**Immunohistochemistry**

Refer to the Supplementary Material (online) for a description of the immunohistochemistry procedures.

**Statistics**

Results are reported as mean ± SEM. The Mann–Whitney U-test was used with GraphPad Prism version 5.00 for Windows (www.graphpad.com/). p ≤ 0.05 was considered statistically significant.

**Results**

**Treatment of lung grafts with AAT**

We determined the levels of AAT 4 hours after lung transplantation in transplanted mice with grafts stored in AAT (1 mg/ml in Perfadex) by Western blotting (Figure 1A and B). This procedure resulted in a sustained local deposition of AAT in the transplanted lungs in the absence of plasma proteins (Figure 1B).

**AAT treatment during storage improves primary graft function**

Primary graft dysfunction after prolonged cold storage of the left mouse lung in Perfadex was observed using the mouse orthotopic left lung transplantation model (Figure 1B). Cellular infiltrates in the transplanted left lung lobe and neutrophils in the BAL fluid were clearly noticed. After

![Figure 1](image-url) Storage of lung grafts in AAT containing Perfadex results in high AAT levels after 4 hours of reperfusion. (A) Experimental set-up for perfusion, cold ischemic storage, transplantation, and reperfusion. Donor lungs were perfused with AATm or albumin in Perfadex and stored in the respective solutions at 4°C for 18 hours (cold ischemia). Thereafter, the left lung was orthotopically transplanted to the C57BL/6J recipient mice. The transplanted animals were kept alive for 4 hours (reperfusion) before Western blot analysis. (B) Western blot of total lung tissue lysates of transplanted left lungs of 4 C57BL/6J recipient mice after 4 hours of reperfusion using an AAT-specific monoclonal antibody. Immunodetection of β-actin served as a loading control (lower panel). The AAT-specific antibody did not cross-react with endogenous mouse proteins (left panel).
interrupting the blood flow from the non-transplanted right lung, the oxygen pressure in the left heart ventricle decreased, indicating graft dysfunction after prolonged ischemic storage in the cold. To prevent primary graft dysfunction after prolonged storage, we explored the potential beneficial effect of the protease inhibitor AAT by perfusing and storing the lung graft in AAT containing Perfadex at 4°C. We directly compared the AAT with albumin as 2 similar proteinaceous supplements at the same concentration in our mouse transplantation model (Figure 2). As envisaged, we found a highly significant protective effect for AAT on graft preservation at both the histopathologic (Figure 2A) and functional levels (Figure 2B and E). The addition of AAT resulted in almost 40% higher oxygenation of the blood (Figure 2B) in the transplanted left lung. The protein and neutrophil content of the BAL fluid (Figure 2C and D) and the neutrophil infiltration of the transplanted lung (Figure 2E) were much lower in AAT-treated lungs than in the albumin-treated lungs after 4 hours of reperfusion.

**Non-inhibitory AAT has no effect on graft preservation**

To explore the potentially pleiotropic effects of AAT in graft protection, we separated the anti-proteolytic functions of the reactive center loop from other AAT-associated modulatory functions on the remaining surface of the AAT molecule. To eliminate trypsin-, chymotrypsin- or elastase-targeting specificity, we substituted 2 residues in the reactive center loop by aspartate residues at the P4 and P2 position and the 2 residues at P3 and P1 by a proline and serine, respectively (Figure 3A). Changing the P4 Ala-355 and the P2 Pro-357 to a negatively charged Asp eliminates the hydrophobic nature of the reactive center loop and reduces potential interactions of AAT with phospholipid bilayers. Shifting the Pro-357 to position 356 (P3) and replacing the methionine-358 conservatively by a serine alters the canonical inhibitory conformation and β-pleated strand extension of the reactive center loop (P4 to P3′) and its specificity, both of which are required for inhibition of serine proteases.

In accordance with our predictions, murine and human neutrophil elastase (NE) and proteinase 3 (PR3) were not inhibited by AATmt (Figure 3B) produced in HEK293 cells, whereas the purified recombinant AATwt inhibited human and mouse NE and PR3 irreversibly. The sequence modifications of AAT introduced into the reactive center loop were intentionally designed to abolish its cleavability by various mammalian proteases, as assessed using Prosper, Cascleave 2.0, and PeptideCutter. In the lung transplantation experiments with AATmt in direct comparison to albumin, acute lung inflammation, as judged from histology sections (Figure 3C), oxygenation of blood in the transplanted left lobe (Figure 3D), and the protein content in the BAL fluid (Figure 3E and F), was indistinguishable between the 2 treatment groups.

**PR3/NE double-deficient mice demonstrate enhanced primary graft function**

To further corroborate the detrimental role of neutrophil serine proteases in primary graft dysfunction, we examined
wild-type and PR3/NE double-deficient mice as graft recipients with the same genetic background (C57BL/6J) as the donor mice. The lung tissue of the transplanted lobe in the double-knockout mice showed a healthier alveoli structure than that of wild-type mice after 4 hours of reperfusion, as assessed by H&E staining (Figure 4A). Gas-exchange function of the transplanted lobe was clearly preserved after 4 hours of exposure to blood of PR3- and NE-deficient mice, whereas the lung graft in wild-type recipient mice performed poorly (Figure 4B). The mean partial pressure of oxygen was 80% in the arterial blood of the left ventricle of knockout mice compared with 50% in wild-type recipients after clamping of the right bronchus. The degree of protein exudation (Figure 4C) and cellular content of neutrophils in the BAL fluid (Figure 4D) were not significantly different between the knockout and the wild-type recipient groups.

Discussion

Cold storage of human lung grafts for > 6 hours is known to increase the risk of early graft dysfunction after transplantation. Likewise, we found that the left lung in mice stored for 18 hours in a colloid-based electrolyte solution (Percodex) displayed primary graft dysfunction after transplantation. However, when we perfused and stored the lung graft in Percodex containing AAT (1 mg/ml), we were able to significantly reduce the immediate inflammatory response after reperfusion of the transplanted lung. Moreover, we demonstrated that the protective effect of AAT was
mediated by the inhibitory function of AAT targeting the major serine proteases of neutrophils, NE and PR3.

We assume that the AAT of the preservation solution diffuses into the perivascular and interstitial space during perfusion and storage of the donor transplant and is, therefore, optimally deployed in advance to protect the lung tissue against the influx of adhering and extravasating neutrophils around the capillaries and venules. During reperfusion the anti-protease shield of AAT against elastase and other serine proteases of neutrophils appears to represent the most pivotal mechanism of lung preservation in this clinical setting. However, multiple alternative mechanisms of tissue protection and anti-inflammation by AAT unrelated to its anti-protease functions have been reported.21–28

To clarify the major therapeutic mechanism of AAT in immediate graft protection, we chose to separate the anti-proteolytic functions of the reactive center loop from other potential functions on the remaining surface of the AAT molecule. The inhibitory function of AAT primarily targets NE and PR3 and, to a much lesser extent, other proteases like cathepsin G and trypsin-like enzymes.13,29–32 Serine proteases occur in the oxidizing extra- and pericellular environment or within the secretory route, including storage granules, and are active at neutral pH after regulated secretion. Thus, inhibition of proteases in the cytosol after membrane binding,19 endocytosis,33 and translocation to the cytosol34,35 was unlikely. Inhibition of caspases,21,36 and calpain13 in the cytosol have been inferred to be responsible for additional anti-inflammatory properties of the wild-type AAT. Our results strongly suggest that other, non-protease-mediated functions of AAT do not contribute significantly to organ protection during the early phase of reperfusion after transplantation surgery.

In agreement with the findings using the non-inhibitory AAT variant, we found that PR3/NE double-deficient mice exhibited improved primary graft functions compared with wild-type mice. The murine homologs of human PR3 and NE are exclusively expressed in the myelomonocyte lineage and constitutively stored in primary granules of neutrophils.31 Deficiency of these 2 proteases in the germ-line does not have a biological or developmental impact on peripheral tissues and organs and does not cause any phenotype under normal housing and living conditions.15 Hence, these mice were optimally suited to clarify the role of neutrophil serine proteases after initiating reperfusion of the lung graft (Figure 4). Taken together, these findings in knockout mice are consistent with recent observations in macaques after prolonged inhibition of cathepsin C, which resulted in the depletion of serine proteases in neutrophils.38 Under these experimental pharmacologic conditions, neutrophil migration and recruitment to the lungs and bronchi was not altered in response to tracheal lipopolysaccharide instillation.

The preservation procedure assessed in this pre-clinical study corresponds very closely to the graft-handling procedure in the routine thoracoscopic setting. AAT at a final concentration of 1 mg/ml added to Perfadex solution is a safe and easily acceptable modification of the most widely used preservation solution, as this natural human plasma protein has already been approved for long-term substitution therapy in emphysema patients with constitutively low levels of AAT in their blood. In the absence of other plasma proteins, flushing and perfusion with 1 mg/ml
(15 μmol/liter) AAT in Perfadex solution suffices to deliver this inhibitor to endothelial cells and the interstitial lung space after lung removal from the brain-dead donor. In the absence of competing proteins, endocytosis and transcytosis of AAT from the Perfadex solution by the lung endothelium is presumably more efficient than its uptake from whole blood even then, when additional AAT is infused intravenously prior to the operation.

Ex vivo perfusion of the lung graft with AAT clearly has a great advantage over its systemic delivery in the donor and recipient, not only because this protocol complies with current ethical standards. Moreover, with this procedure, we achieved maximum tissue levels of AAT in advance, before the first neutrophils, together with soluble plasma components from the recipient reach the transplanted lungs after connecting the lungs to the patient’s circulation. Treatment of the graft recipient with AAT before and after surgery is clearly a complementary therapeutic option, as shown in a previous study. Patients with severe chronic obstructive pulmonary disease (COPD) show increased elastase activity of AAT from the Perfadex solution by the lung endothelium is presumably more efficient than its uptake from whole blood even then, when additional AAT is infused intravenously prior to the operation.

Local deposition of AAT in the graft cannot stop or significantly delay the ischemia-induced metabolic and structural changes of the graft. Cellular instability and breakdown is expected to increase even with AAT storage beyond the 6-hour period. Residential neutrophils, however, retained in the graft, are also affected by this process and presumably release a limited amount of preformed pro-inflammatory mediators, including serine and matrix metalloproteases. In contrast to matrix metalloproteases, neutrophil serine proteases are fully processed and stored in acidic primary granules, but are immediately active in a neutral (pH 7) environment in the absence of AAT. Because the PR3/NE-deficient recipient mice also showed improved graft function, we conclude that infiltrating neutrophils and macrophages of the recipient executed the majority of tissue damage during reperfusion at body temperature, and that this immediate attack by leukocytes could be counterbalanced by a local protection shield against proteases.

It remains to be clarified how long the local effects of AAT are maintained in the transplanted lung and can favorably affect a later immune response. Negative side effects of AAT in lung transplantation are conceivable in view of a delayed neutrophil response, which may favor bacterial lung infections during or directly after surgery. In a previous clinical attempt to reduce primary lung dysfunction with aprotinin, a bovine inhibitor, the study had to be stopped prematurely as renal toxicity of aprotinin was discerned. The organ conservation procedure, which we propose here on the basis of an appropriately designed small-animal study with human AAT, appears to be relatively safe, ethically acceptable, clinically translatable, and well-supported by long-standing clinical research on AAT. In addition, the procedure may be applicable to organ transplantation surgery in general.

Disclosure statement

The authors have no conflicts of interest to disclose. This study was supported by grants from the European Union’s Horizon 2020 Research and Innovation Program (668036, RELENT) and the CPC Research School “Lung Biology and Disease”. Responsibility for the information and views set out in this article lies entirely with the authors.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at www.jhltonline.org/.

References


